CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 364,654	$ 492,860
Marketable securities	4,550	4,941
Prepaid expenses	7,560	5,354
Other current assets	1,313	1,348
Total current assets	378,077	504,503
Property and equipment, net of accumulated depreciation and amortization of $6,866 and $4,316 at September 30, 2019 and December 31, 2018, respectively	33,386	23,469
Other long-term assets	267	68
Total Assets	411,730	528,040
Current Liabilities:
Accounts payable and accrued expenses	54,596	31,722
Liability related to sale of future royalties - current	3,141	0
Lease liability - current	316
Total current liabilities	58,053	31,722
Convertible senior notes, net	7,093	7,055
Liability related to sale of future royalties - non-current	248,176	221,295
Deferred revenues	65,000	0
Other long-term liabilities	10,052	2,119
Total Liabilities	388,374	262,191
Commitments and Contingencies
Stockholders' Equity:
Convertible preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at September 30, 2019 and December 31, 2018	0	0
Common stock, $0.01 par value; authorized 250,000,000 shares; issued 191,995,708 shares and outstanding 191,876,087 shares at September 30, 2019; issued 190,445,795 shares and outstanding 190,411,070 shares at December 31, 2018	1,920	1,905
Capital contributed in excess of par	1,235,930	1,219,237
Treasury stock, at cost: 119,621 shares at September 30, 2019 and 34,725 shares at December 31, 2018	(2,095)	(824)
Accumulated deficit	(1,210,798)	(953,216)
Accumulated other comprehensive loss	(601)	(351)
Total Immunomedics, Inc. stockholders' equity	24,356	266,751
Noncontrolling interest in subsidiary	(1,000)	(902)
Total stockholders' equity	23,356	265,849
Total Liabilities and Stockholders' Equity	$ 411,730	$ 528,040